Terapia Nutricional na evolução da Gangliosidose GM1: um relato de caso

Authors

  • Mariana Barros de Souza Residência Multiprofissional em Atenção Hospitalar, Hospital Universitário da Universidade Federal de Juiz de Fora/HU Brasil, Minas Gerais, Brasil. https://orcid.org/0009-0000-2016-4852
  • Chislene Pereira Vanelli Unidade Multiprofissional, Serviço de Nutrição, Hospital Universitário da Universidade Federal de Juiz de Fora/HU Brasil, Juiz de Fora, Minas Gerais, Brasil. https://orcid.org/0000-0002-2041-672X

DOI:

https://doi.org/10.34019/1982-8047.2026.v52.53784

Keywords:

Português

Abstract

Introduction: GM1 gangliosidosis is a rare lysosomal storage disorder caused by β-galactosidase deficiency, resulting in progressive neurological impairment. Clinical management is predominantly palliative, and nutritional care is essential for preventing complications and maintaining nutritional status. Objective: To describe the nutritional follow-up of a pediatric patient with GM1 gangliosidosis. Case Report: This observational and descriptive study reports the case of a male patient born at term who presented with neuropsychomotor developmental delay and hypotonia from the first month of life. His first hospitalization at the University Hospital of the Federal University of Juiz de Fora, Minas Gerais, Brazil, occurred at 13 months of age, when he was diagnosed with GM1 gangliosidosis. Discussion: The patient required enteral nutrition therapy and continuous nutritional monitoring. During nine hospital admissions, adjustments were made to the composition, volume, and administration method of the enteral feeding regimen to ensure adequate nutritional intake. Initially, the patient experienced mild weight loss, followed by nutritional recovery and progressive weight gain, which was later associated with the development of edema. Conclusion: Nutritional therapy played a key role in the clinical management of this patient with GM1 gangliosidosis. Continuous adaptations to the nutritional regimen were required in response to disease progression and associated clinical complications, highlighting the importance of ongoing nutritional support to meet the evolving demands imposed by the disease.

Downloads

Download data is not yet available.

References

1 Ijaz A, Abbas S, Shabbir M, Badshah Y, Abid F, Afsar T, et al. Inherited metabolic disorders: presentation, clinical types, laboratory diagnosis and genetic markers. Orphanet J Rare Dis. 2025; 20:422. DOI: 10.1186/s13023-025-03979-8.

2 Utz JRJ, Kim S, King K, Ziegler R, Schema L, Redtree ES, et al. Infantile gangliosidoses: mapping a timeline of clinical changes. Mol Genet Metab. 2017; 121(2):170-9. DOI: 10.1016/j.ymgme.2017.04.011.

3 Giugliani L, Steiner CE, Kim CA, Lourenço CM, Santos MLSF, Souza CFM, et al. Clinical findings in Brazilian patients with adult GM1 gangliosidosis. JIMD Rep. 2019; 49(1):96-106. DOI: 10.1002/jmd2.12067.

4 Crary MA, Mann GDC, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005; 86(8):1516-20. DOI: 10.1016/j.apmr.2004.11.049.

5 Krick J, Murphy-Miller P, Zeger S, Wright E. Pattern of growth in children with cerebral palsy. J Am Diet Assoc. 1996; 96(7):680-5. DOI: 10.1016/S0002-8223(96)00188-5.

6 Hulst JM, Zwart H, Hop WC, Joosten KFM. Dutch national survey to test the STRONGkids nutritional risk screening tool in hospitalized children. Clin Nutr. 2010; 29(1):106-11. DOI: 10.1016/j.clnu.2009.07.006.

7 Rokusek C, Heinrichs E. Nutrition and feeding of the developmentally disabled. Brookings: South Dakota University Affiliated Program, Interdisciplinary Center for Disabilities; 1985.

8 Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington: The National Academies Press; 2005.

9 Garcia-Iborra M, Castanys-Munoz E, Oliveros E, Ramirez M. Optimal protein intake in healthy children and adolescents: evaluating current evidence. Nutrients. 2023; 15(7):1683. DOI: 10.3390/nu15071683.

10 Marchand V, Motil KJ, NASPGHAN Committee on Nutrition. Nutrition support for neurologically impaired children: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition [Internet]. J Pediatr Gastroenterol Nutr. 2006 [citado em 2026 jul. 17]; 43: 123-35. Disponível em: https://naspghan.org/files/documents/pdfs/position-papers/nutriSupportNeuro_Impaired_Child.pdf.

11 Lage FB. Recomendação proteica para crianças com síndrome nefrótica [Internet]. Rev Bras Nutr Clin. 2014 [citado em 2026 jul.17]; 29(4):360-6. Disponível em: http://www.braspen.com.br/home/wp-content/uploads/2016/11/15-Recomenda%C3%A7%C3%A3o-proteica.pdf.

12 D'Souza P, Farmer C, Johnston JM, Han ST, Adams D, Hartman AL, et al. GM1 gangliosidosis type II: results of a 10-year prospective study. Genet Med. 2024; 26(7):101144. DOI: 10.1016/j.gim.2024.101144.

13 Lang FM, Korner P, Harnett M, Karunakara A, Tifft CJ. The natural history of Type 1 infantile GM1 gangliosidosis: a literature-based meta-analysis. Mol Genet Metab. 2020; 129(3):228-35. DOI: 10.1016/j.ymgme.2019.12.012.

14 Arash-Kaps L, Komlosi K, Seegräber M, Diederich S, Pashke E, Amraoui Y, et al. The clinical and molecular spectrum of GM1 gangliosidosis. J Pediatr. 2019; 215:152-7.e3. DOI: 10.1016/j.jpeds.2019.08.016.

15 Bingaman A, Waggoner C, Andrews SM, Pangonis D, Trad M, Giugliani R, et al. GM1-gangliosidosis: the caregivers' assessments of symptom impact and most important symptoms to treat. Am J Med Genet A. 2023; 191(2):408-23. DOI: 10.1002/ajmg.a.63038.

16 Zhao Y, Tang H, Peng T, Li J, Liu L, Fu C, et al. Research GROUP. Relationship between nutritional status and severity of cerebral palsy: a multicentre cross-sectional study. J Rehabil Med. 2023; 55:jrm00367. DOI: 10.2340/jrm.v55.4395.

17 Anderson AK, Burke K, Bendle L, Koh M, McCulloch R, Breen M. Artificial nutrition and hydration for children and young people towards end of life: consensus guidelines across four specialist paediatric palliative care centres. BMJ Support Palliat Care. 2021; 11(1):92-100. DOI: 10.1136/bmjspcare-2019-001909.

18 Lal K, Perveen A. Nephrotic syndrome in children: a review. Medicine (Baltimore). 2026; 105(11):e47921. DOI: 10.1097/MD.0000000000047921.

19 Lella G, Pecoraro L, Benetti E, Arnone OC, Piacentini G, Brugnara M, et al. Nutritional management of idiopathic nephrotic syndrome in pediatric age. Med Sci (Basel). 2023; 11(3):47. DOI: 10.3390/medsci11030047.

20 Dienstmann G, Souza MLR, Bergmann FH, Castanhel FD, Simão CS, Bohnert L, et al. GM1 gangliosidosis: a case report. Jornal Brasileiro de Patologia e Medicina Laboratorial. 2021; 57:1–5. DOI: 10.5935/1676-2444.20210043.

Published

2026-11-17

How to Cite

1.
Souza MB de, Vanelli CP. Terapia Nutricional na evolução da Gangliosidose GM1: um relato de caso. HU Rev [Internet]. 2026 Nov. 17 [cited 2026 Nov. 17];52:1-7. Available from: https://periodicos.ufjf.br/index.php/hurevista/article/view/53784

Issue

Section

Relato de Caso

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.